Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
- Authors
- Kim, Hyun Jin; Park, Seok O.; Ko, Seung-Hyun; Rhee, Sang Youl; Hur, Kyu-Yeon; Kim, Nan-Hee; Moon, Min Kyong; Lee, Byung-Wan; Kim, Jin Hwa; Choi, Kyung Mook
- Issue Date
- 12월-2017
- Publisher
- KOREAN DIABETES ASSOC
- Keywords
- Cardiovascular benefit; Clinical practice guideline; Combination therapy; Glucagon-like peptide-1 receptor agonist; Hypoglycemia; Monotherapy
- Citation
- DIABETES & METABOLISM JOURNAL, v.41, no.6, pp.423 - 429
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- DIABETES & METABOLISM JOURNAL
- Volume
- 41
- Number
- 6
- Start Page
- 423
- End Page
- 429
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/81464
- DOI
- 10.4093/dmj.2017.41.6.423
- ISSN
- 2233-6079
- Abstract
- The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.